Romain BUISSON/LinkedIn
Nov 5, 2025, 05:14
Penumbra Announces Secondary Results of the Ground-Breaking STORM – PE RCT
Romain Buisson, Country Manager (TH-HK cluster) at Penumbra, Inc., shared a post by Penumbra, Inc. on LinkedIn:
”Latest updates in STORM PE
Patient treated with CAVT plus anticoagulation experienced significantly longer distance walked during the 90-day six-minute walk test (472m vs 376m; P = 0.019).
CAVT patients near normalized by 90 days, walking 94% of their predicted walk distance vs 75% in the anticoagulation only arm (P = 0.022)”
Quoting Penumbra, Inc.’s post:
”Penumbra announces secondary results of the ground-breaking STORM-PE RCT at VIVA 2025. Read more here.”
Stay updated with Hemostasis Today.
-
Jun 15, 2026, 18:24Celebrating Emna Gouider’s Renewed Leadership at WFH Congress 2026 – WFH
-
Jun 15, 2026, 18:14Anastasia Conti: Connecting Celebrating and Advancing Hematology at EHA 2026
-
Jun 15, 2026, 18:01Eric Mwenda: Honoring Blood Donors and Partnerships in Tanzania
-
Jun 15, 2026, 17:37Vincent Elsey: The Ethereal Anatomy of a Broken Vessel
-
Jun 15, 2026, 17:20Megan Adediran: Small Act, Massive Impact – Celebrating Blood Donor Day
-
Jun 15, 2026, 16:52Alejandro González Veliz: A Modern Approach to Anticoagulant Management
-
Jun 15, 2026, 16:20New Therapeutic Strategies Targeting Iron Metabolism
-
Jun 15, 2026, 15:43Antonio Paul: Donor Safety Is More Than a Sterile Needle
-
Jun 15, 2026, 15:36Alejandro González Veliz: A Coronary Calcium Score of Zero Doesn’t Always Mean Zero Risk